Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistNeva Global Grup Sanayi, a Turkish drug manufacturer, violated Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals during an FDA inspection in September 2024. The company failed to conduct identity testing on drug components and active ingredients used in over-the-counter products, and relied on suppliers' certificates of analysis without establishing the reliability of those suppliers' test methods at appropriate intervals, as required by 21 CFR 211.84(d). These manufacturing and control deficiencies rendered the firm's drug products adulterated under the Federal Food, Drug, and Cosmetic Act.